Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
Deloitte
Cipla
Healthtrust
Harvard Business School
Dow
Medtronic
Covington
UBS
Express Scripts

Generated: January 20, 2018

DrugPatentWatch Database Preview

Claims for Patent: 5,763,493

« Back to Dashboard

Summary for Patent: 5,763,493
Title: Stabilized pharmaceutical
Abstract:This application discloses a method of inhibiting degradation of the antidepressant bupropion hydrochloride in a solid pharmaceutical formulation, so that the pharmaceutical formulation will maintain at least 80% of its initial bupropion potency after one year.
Inventor(s): Ruff; Michael D. (Greenville, NC), Kalidindi; Sanvasi R. (Edison, NJ), Sutton, Jr.; Joel Elmore (Greenville, NC)
Assignee: Glaxo Wellcome Inc. (Research Triangle Park, NC)
Application Number:08/667,239
Patent Claims: 1. A pharmaceutical composition in solid form comprising bupropion hydrochloride and a pharmaceutically acceptable stabiliser in an effective stabilising amount, in which the composition contains at least about 80% w/w of undegraded bupropion hydrochloride after storage for 6 weeks at about 40.degree. C. and 75% relative humidity and in which an aqueous solution of the stabiliser in a concentration of about 6% w/w has a pH of about 0.9 to about 4, the stabiliser being selected from the group consisting of L-cysteine hydrochloride, glycine hydrochloride, malic acid, sodium metabisulfite, citric acid, tartaric acid and L-cystine dihydrochloride.

2. A pharmaceutical composition according to claim 1, wherein the aqueous solution of the stabiliser has a pH of about 09. to 2.

3. A pharmaceutical composition according to claim 1, wherein the aqueous solution of the stabiliser has a pH of around 1.

4. A pharmaceutical composition according to claim 1, 2 or 3 which contains at least about 90% w/w of undegraded bupropion hydrochloride after storage for 6 weeks.

5. A pharmaceutical composition according to claims 1, 2 or 3 which contains at least 95% w/w of undegraded bupropion hydrochloride.

6. A pharmaceutical composition according to claims 1, 2 or 3 which contains at least 98% w/w of undegraded bupropion hydrochloride.

7. A pharmaceutical composition according to claims 1, 2 or 3, wherein the amount of stabiliser is 2.7% to 27% of the weight of bupropion hydrochloride in the composition.

8. A pharmaceutical composition according to claims 1, 2 or 3, wherein the amount of stabiliser is 5% to 16.2% of the weight of bupropion hydrochloride in the composition.

9. A tablet or capsule containing a composition according to claims 1, 2, or 3, wherein the amount of bupropion hydrochloride is 25 to 500 mg.

10. A tablet or capsule containing a composition according to claims 1, 2, or 3, wherein the amount of bupropion hydrochloride is 25 to 300 mg.

11. A tablet or capsule containing a composition according to claim 1, 2, or 3, wherein the amount of bupropion hydrochloride is 50, 75, 100 or 150 mg.

12. A method of stabilizing bupropion hydrochloride in a solid pharmaceutical composition so that at least about 80% w/w of bupropion hydrochloride is present in the undegraded form after storage for 6 weeks at about 40.degree. C. and 75% relative humidity, wherein said method comprises mixing bupropion hydrochloride with a stabiliser of which an aqueous solution in a concentration of about 6% w/w has a pH of about 0.9 to about 4, the stabiliser being selected from the group consisting of L-cysteine hydrochloride, glycine hydrochloride, malic acid, sodium metabisulfite, citric acid, tartaric acid and L-cystine dihydrochloride.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Federal Trade Commission
Boehringer Ingelheim
Daiichi Sankyo
Julphar
Mallinckrodt
AstraZeneca
QuintilesIMS
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot